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We evaluated retrospectively the effect of perioperative blood transfusions 
on survival in esophageal cancer. The records of all patients who underwent 
esophageal resection (n = 316) at UCLA Medical Center from 1970 to 1993 
were reviewed. Statistical analysis included univariate (log-rank X 2) and 
multivariate (Cox proportional hazards) analyses with other known risk 
factors. High-volume blood transfusions (>8 units) but not low-volume 
blood transfusions (1 to 8 units) were associated with a significant decrease 
in long-term survival (median survival: no transfusion, 22 months; low- 
volume blood transfusion, 14.5 months, versus high-volume blood transfu- 
sions, 6.5 months;p < 0.01). Multivariate analysis revealed that the shorter 
survival with high-volume blood transfusions was a result of an increased 
number of postoperative complications. High-volume blood transfusions 
were not associated with increases in tumor recurrence or infectious 
complications. The association between shorter survival and high-volume 
blood transfusions in esophageal cancer may, therefore, be because of the 
circumstances necessitating transfusion rather than any immunosuppres- 
sive effects of the transfused blood. These findings suggest that the 
transfusion of blood does not by itself decrease the chance of cure after 
esophageal resection. (J Thorac Cardiovasc Surg 1996;112:341-8) 
p erioperative blood transfusions have been asso- 
ciated with decreased survival in various types of 
cancer, including colorectal, lung, hepatocellular, 
gastric, head and neck, renal, prostate, and sar- 
coma. 1-s No study to date has evaluated the effect of 
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perioperative blood transfusions on survival in 
esophageal cancer. Furthermore, many of these 
prior studies failed to control for all prognostic 
factors, including the preoperative status of the 
patient, tumor stage, and perioperative outcome. 
We set out, therefore, to evaluate the effect of 
transfusions of blood and other serum-based prod- 
ucts (fresh-frozen plasma [FFP], albumin, and plate- 
lets) on survival after esophageal resection. Our 
study involved multivariate analysis with other prog- 
nostic factors and sought to determine whether 
blood transfusions were an independent risk factor 
for decreased survival in esophageal cancer. 
Methods 
Patient data. The hospital records of all patients (n = 
316) who underwent esophageal resection because of 
adenocarcinoma or squamous cell carcinoma t UCLA 
Medical Center between January 1, 1970, and June 1, 
1993, were reviewed. To assess the role of perioperative 
blood transfusions on long-term survival, all patients who 
did not undergo complete resection of the primary tumor 
were excluded, along with patients who died within 30 
days of operation. A total of 275 patients fit the study criteria 
and these cases were carefully reviewed for various factors, 
including age, race, tumor location, histologic type, grade, 
pathologic and clinical stages, presenting symptoms, and 
preoperative medical history and performance status. 
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Fig. 1. No significant decrease was seen in overall survival duration of patients who underwent esophageal 
resection and received blood transfusions. Median survival of patients who received no blood transfusion 
(lineA, n = 61) was 21.8 months and for those who received blood (line B, n = 191) was 13.7 months (p = 
o.11). 
Complete perioperative data on blood-product transfu- 
sion were available for 252 patients and were used for 
survival analysis. The perioperative period was defined as 
48 hours before and 48 hours after operation. Experi- 
enced surgeons were defined as those who had done more 
than 10 esophagectomies. Patient treatment during this 
period was carefully evaluated for the amount and types of 
fluid transfused (packed red blood cells [PRBC], whole 
blood, autologous blood, platelets, FFP, albumin, and 
crystalloid), the number and duration of hypotensive 
episodes (defined as periods with mean arterial pressure 
less than 80% of preoperative value), and need for 
inotropic support. The operative and anesthesia times, 
blood loss, type of operation, and location of anastomoses 
were recorded. 
Short-term outcome was assessed by the number and 
types of postoperative complications, including the need 
for extended hospitalization and reoperation. Postopera- 
tive changes in laboratory values were assessed 3 days 
after operation and included lymphocyte counts, hemato- 
crit values, liver function test results, and coagulation 
profiles. Long-term outcome was determined by review of 
outpatient records and through the database of the UCLA 
Tumor Registry. Recurrences, postoperative treatments, 
and status at most recent follow-up were noted. 
Statistical analysis. Statistical analysis was done only 
on the 275 patients who underwent complete resections of 
the primary tumor and did not die within 30 days. 
Univariately, Xa (log likelihood ratio) tests were used for 
estimating and comparing death rates on the basis of the 
Poisson distribution. Conditional Poisson methods were 
used to estimate confidence bounds. Product-limit sur- 
vival curves were computed by the methods of Kaplan and 
Meier and the log-rank test was used for comparing 
survival curves. Multivariately, the stepwise Cox propor- 
tional hazards model was used to simultaneously assess 
the impact of many factors on survival. Liberal (p < 0.10) 
inclusion criteria were used for variable inclusion. The 
SAS statistical package (SAS Institute, Cary, N.C.) was 
used for all analyses. Statistical significance was accepted 
as p < 0.05. 
Results 
Effect of blood transfusions on survival duration 
in esophageal cancer. Complete records were avail- 
able for 252 patients. Preoperative chemotherapy 
was used in 28 patients and preoperative radiation 
therapy was used in 47. A total of 30 surgeons 
performed esophagectomies, but three surgeons 
performed the majority of the operations (141/252, 
56%). Transthoracie resection was used in 207 pa- 
tients (Ivor-Lewis, 190; left side of the chest, 12; 
right side of the chest and neck anastomosis, 5), 
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whereas 45 patients underwent transhiatal esoph- 
agectomy. A total of 191 patients (76%) received 
blood products (PRBC, whole blood, or autolo- 
gous), whereas 61 patients (24%) received no trans- 
fusions. The amount of blood transfused was 0 units 
in 61 patients (24%), 1 to 4 units in 116 patients 
(46%), 5 to 8 units in 48 patients (19%), and more 
than 8 units in 27 patients (11%). 
The median survival duration of patients who did 
not receive blood was 21.8 months whereas that of 
patients who did receive blood was 13.7 months 
(Fig. 1). This difference approached significance 
(p = 0.11) when subjected to log-rank X a analysis. 
Univariate analysis of the risk relative to the amount 
of blood transfused showed that the risk rose dra- 
matically with transfusions greater than 8 units 
(Table I). Multivariate analysis confirmed a blood 
transfusion threshold of 8 units, above which the risk 
ratio rose from 1.12 to 2.16 (Table II). When the 
amount of blood transfused exceeded 8 units the 
median survival was 6.5 months (p < 0.01) com- 
pared with 14.5 months for 1 to 8 units and 22 
months for no blood transfusion (Fig. 2). 
Multivariate analysis of the effect of perioperative 
blood transfusion. High-volume blood transfusion 
was associated with significantly more intraoperative 
blood loss, hypotension, and transfusions ofalbumin 
and crystalloid. No difference was seen between 
groups in preoperative status or tumor extent. Be- 
cause of these observed perioperative differences, a 
univariate analysis was done with 45 other risk 
factors, including tumor characteristics, preopera- 
tive patient status, and perioperative treatments o
determine significant variables to evaluate multiva- 
riately (Table III). With use of a liberal inclusion 
scheme (p < 0.10) all factors deemed significant 
with univariate analysis were evaluated by multivar- 
iate analysis. The five significant prognostic factors 
for esophageal cancer in multivariate analysis were 
four measures of tumor extent (grade, depth, lymph 
node status, and presence of metastases) and one 
perioperative factor (high-volume blood transfu- 
sions of >8 units) (Table I). Other factors such as 
blood loss, anastomosis location, FFP transfusion, 
platelet and albumin transfusion, gender, clinical 
tumor stage, tumor size, alcohol use, hematocrit 
value at admi~ssion to the hospital, percent of posi- 
tive lymph nodes, distant recurrence, lymphocyte 
count, duration of intensive care unit (ICU) stay, 
surgeon experience, year of procedure, and percent 
tumor necrosis were associated with decreased sur- 
vival duration in univariate analysis but did not 
Table I. Relative risk of dying as a function of 
number of transfusions (univariate analysis) 
95% 
Transfusions No. of Death Relative Confidence p 
(units) patients rate* risM intelval Value¢ 
Missing 23 3.22 - -  - -  - -  
0 61 3.06 1.00 - -  - -  
1 24 4.61 1.51 0.85, 2.66 0.1160 
2 41 4.25 1.39 0.88, 2.20 0.1217 
3 26 2.13 0.52 0.39, 1.24 0.2606 
4 26 1.63 0.53 0.29, 0.96 0.0385 
5 16 7.68 2.51 1.37, 4.60 0.0026 
6 12 2.83 0.92 0.44, 1.93 0.9997 
7 10 2.77 0.91 0.42, 1.96 0.9781 
8 9 1.90 0.62 0.26, 1.49 0.3678 
9 3 33.80 11.05 2.59, 47.05 0.0018 
10 6 10.03 3.28 1.27, 8.46 0.0117 
11 4 11.60 3.79 1.33, 10.82 0.0106 
12 3 15.03 4.91 1.48, 16.26 0.0079 
13 1 0.00 0.00 - -  - -  
14 2 11.95 3.91 0.92, 16.63 0.0321 
15+ 8 21.73 7.10 3.27, 15.41 0.0001 
Total 275 3.30 1.08 0.91, 1.28 - -  
*Death rate per 100 patient-months. 
?Relative risk compared with 0 units. 
$Statistical significance: p -< 0.05. 
remain significant in multivariate analysis. Even at 
very high volumes, transfusion ofother serum-based 
products (FFP, platelets, albumin) had no effect on 
survival duration in multivariate analysis. There 
were no significant differences in survival among 
types of blood transfused (PRBC, whole blood, or 
autologous blood) or timing of transfusion (preop- 
erative, intraoperative, or postoperative). High-vol- 
ume blood transfusion was associated with a risk 
ratio of 2.17 compared with the risk ratios of grade 
(1.44), depth (1.37), lymph node status (2.28), and 
metastases (3.36). 
Short- and long-term outcomes of patients receiv- 
ing high-volume blood transfusions. We further 
evaluated the short- and long-term outcomes of 
patients receiving high-volume blood transfusion 
(Table IV). No increase was noted in the rates of 
local or distant umor ecurrence after high-volume 
blood transfusion. Furthermore, the rates of infec- 
tious complications were similar between the two 
groups. Patients who received high-volume blood 
transfusion also had a much higher risk of the 
development of more than four complications in the 
postoperative course (high-volume blood transfu- 
sion, 7/27 [26%] versus no transfusion or low- 
volume blood transfusion, 3/225 [1%]; p < 0.0001), 
with increases in the lengths of both ICU and 
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Fig. 2. Subset of patients who received high-volume blood transfusions (>8 units) during esophageal 
resection had significant decrease in survival duration. Median survival for patients who received no 
transfusion (line A, n = 61) was 22 months, for those who received low-volume transfusion (line B, 1 to 8 
units, n = 164) 14.5 months, and for those who received high-volume transfusion (line C, >8 units, n = 27) 
6.5 months (p < 0.001). 
Table II. Risk of dying as a result of blood 
transfusions controlling for other risk factors 
(Cox model) *
Relative 95% p 
Factor risk Confidence interval Value? 
Blood transfused 
0 units 1.00 - -  - -  
1-4 units:) 0.96 0.64, 1.43 0.84 
4-8 units$ 1.02 0.63, 1.65 0.95 
>8 units:~ 2.14 1.14, 4.01 0.01 
Lymph nodes 2.29 1.56, 3.35 0.0001 
Poor grade 1.43 1.04, 1.97 0.03 
Depth 1.37 1.09, 1.72 0.006 
Metastases 3.36 1.98, 5.70 0.0001 
*Multivariate analysis performed with factors listed in table and other 
significant univariate factors including blood loss, hypotension, gender, 
alcohol use, transfused platelets, FFP, and albumin, hematocrit value on 
hospital admission, tumor necrosis, weight loss, len~h of ICU stay, lympho- 
cyte count, experience ofsurgeon, year of procedure, pathologic stage 1, stage 
2A, stage 2B, stage 3, stage 4, lymph node positive percent, distant recurrence, 
operative blood use, Barrett's esophagus, and positive margins. 
"~StatisticaI significance: p -< 0.05. 
~+Relative risk compared with 0 units. 
regular hospital stays (Table IV). These complica- 
tions occurred within 30 days of the operation and 
were associated with a significantly shorter survival 
(those with more than four complications had a 5-year 
survival of 0%, whereas those who had fewer compli- 
cations had a 5-year survival of 24%; p < 0.0001) (Fig. 
3). The cause of death after high-volume blood trans- 
fusion was tumor recurrence in three patients, pulmo- 
nary failure in four patients, and late reoperations in
three patients. This poor outcome xplains in part the 
low overall survival of patients receiving high-volume 
blood transfusion. In fact, when the number of com- 
plications (>4 versus 0 to 4) was included in the 
multivariate analysis, high-volume blood transfusion 
was no longer a significant predictor of survival dura- 
tion in patients undergoing esophageal resection (Ta- 
ble V). The addition of postoperative complications to
the multivariate analysis had no effect on the other 
four prognostic factors: tumor grade and depth, lymph 
node status, and metastases. 
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Table III. Univariate analyses of selected prognostic 
factors for esophageal cancer 
95% 
Relative Confidence p 
Factor* risk interval Value'/ 
Patient characteristics 
Female gender 0.630 0.45, 0.88 0.0059 
ASA class 1.080 0.86, 1.36 NS 
Karnovsky scale value 1.214 0.98, 1.51 NS 
Cigarette use 0,990 0.74, 1.33 NS 
Alcohol use 1.413 1.01, 1.97 0.0198 
Tumor characteristics 
Histologic type 1.027 0.88, 1.70 NS 
Location 1.027 0.72, 1.47 NS 
Grade 1.663 1.25, 2.20 0.0003 
Size 1.088 1.02, 1.16 0.0063 
Depth 1.745 1.44, 2.11 0.0001 
Lymph nodes 1.085 1.05, 1.12 0.0001 
Metastases 4.902 3.05, 7.88 0.0001 
Perioperative factors 
Operative time 1.001 0.03, 39.97 NS 
Blood loss 1.695 1.20, 2.38 0.0028 
Hypotension 1.056 0.98, 1.14 0.1401 
Inotrope use 1.068 0.78, 1.47 NS 
Perioperative transfusions 
Blood 1.059 1.04, 1.08 0.0001 
High volume (>8 units) 2.137 1.53, 2.98 0.0001 
Platelets 1.102 0.99, 1.32 0.0563 
FFP 1.140 0.93, 1.62 0.0691 
Albumin 1.099 1.04, 1.16 0.0010 
NS, Not significant. 
*Other prognostic factors that were significant in univariate analysis 
included hematocrit value on hospital admission, tumor necrosis, weight 
loss, length of ICU stay, lymphocyte count, experience of surgeon, year of 
procedure, pathologic stage 1, stage 2A, stage 2B, stage 3, stage 4, lymph 
node positive percent, distant recurrence, operative blood use, Barrett's 
esophagus and positive margins. Other prognostic factors that were not 
significant univariately included age, ulceration, lymphocyte count, change 
in lymphocyte count, albumin, creatinine value, transhiatal esophagec- 
tomy, and local recurrence. 
1"Statistical significance: p -< 0.05. 
These findings suggest hat the decreased sur- 
vival duration observed with high-volume blood 
transfusion may not have been caused by high- 
volume blood transfusion, but may only reflect its 
association with the more significant prognostic 
factor of having more than four postoperative 
complications (correlation coefficient r = -0.49, 
p < 0.001). Preoperative factors associated with 
more than four postoperative complications in- 
cluded a history of emphysema and more than 20 
pounds of weight loss. No association was seen 
with age, gender, tumor stage, preoperative che- 
motherapy, or radiation therapy use and increased 
complications. 
Table IV. Postoperative outcome of patients by 
volume of transfusion 
No or low High 
blood volume blood volume 
(0-8 units) (>8 units) p 
(n = 230) (n = 25) Value* 
Tumor recurrence 
Local 9/225 (4%) 2/27 (7%) NS 
Distant 40/225 (18%) 3/27 (11%) NS 
Infectious 38/225 (17%) 6/27 (22%) NS 
complications 
Total no. of 
complications 
0 87/225 (39%) 3/27 (11%) 0.008 
1-4 139/225 (61%) 15/27 (56%) NS 
>5 3/225 (1%) 7/27 (26%) 0.0001 
Postoperative 
days in hospital 
ICU+ 4.3 _+ 0.6 16.8 _+ 16 0.02 
Total? 15.3 + 6.0 21.6 -+ 20.8 0.01 
NS, Not significant. 
*Statistical significance: p -< 0.05. 
1"Value plus or minus tandard deviation. 
Discussion 
Perioperative blood transfusions have been asso- 
ciated with decreased long-term survival in various 
types of cancer, including colorectal, lung, hepato- 
cellular, gastric, head and neck, breast, prostate, 
renal cell carcinoma, and sarcoma. 2' 3, 5, 6, 8-11 Con- 
troversy exists because other reports have shown no 
decrease in survival with transfusions. 12-2° One ex- 
planation for these discrepancies is that some stud- 
ies included patients who died in the perioperative 
period whereas other studies did not. Furthermore, 
not all studies included multivariate analysis with 
important prognostic factors such as tumor stage 
and perioperative outcome. Our study took care not 
to bias long-term tumor survival with poor operative 
outcomes by excluding all patients who died within 
30 days of operation. We also performed multivar- 
iate analysis with other important prognostic factors 
to determine whether blood transfusion was actually 
an independent predictor of long-term survival. 
Even with multivariate analysis, high-volume blood 
transfusion was a significant risk factor for de- 
creased survival (Table III). As has been reported by 
others, this effect was most pronounced at high 
volumes of blood transfusion (Fig. 2), suggesting a
possible threshold effect. 4' 8, 21 
Controversy exists as to whether the decreased 
survival duration observed with perioperative blood 
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Fig. 3. Development of more than four postoperative complications after esophageal resection was 
associated with marked decrease in survival duration. For those who had more than four complications 
(line B, n = 10), 5-year survival was 0%; for those who had four or fewer complications (lineA, n = 242), 
5-year survival was 24% (p < 0.001). 
Table V. Multivariate (Cox model) assessment of prognostic factors in esophageal cancer death with and 
without inclusion of postoperatiVe complications 
Without complications Including complications 
Factor RR 95% CI p Value* RR 95% CI p Value* 
Transfusions (>8 units) 2.17 1.24, 3.80 0.006 1.42 0.6& 2.93 0.34 (NS) 
Complications (>4) Not included 3.44 1.30, 9.10 0.01 
Poor grade 1.44 1.05, 1.98 0.023 1.50 1.09, 2.00 0.01 
Depth 1.37 1.09, 1.71 0.006 1.36 1.09, 1.70 0,001 
Lymph nodes 2.28 1.56, 3.34 0.0001 2.14 1.46, 3:10 0.0001 
Metastases 3.36 1.98, 5,71 0.0001 3.48 1.98, 5.76 0.0001 
RR, Relative risk; CI, confidence interval; NS, not significant. 
*Statistical significance: p -< 0.05. 
transfusions i a result of the causal effect of immune 
suppression by blood or 0f the close association with 
circumstances that necessitate transfusions (that is, 
large tumors that require much manipulation and 
bl0od loss to remove). The immunosuppressive effect 
of,blood transfusion has been documented in other 
studies. The transfusion of blood is known to increase 
kidney transplant survival rates by decreasing episodes 
of rejection. 22 Recurrences of Crohn's disease have 
been reported to decrease after blood transfusion. 23
Furthermore, specific immunorelated abnormalities 
have been documented after blood transfusion, includ- 
ing decreased natural killer cell functiony -26 de- 
pression of macrophage actMty, 27 low lymphocyte 
counts, 28 and increased levels of the immunosuppres- 
sant prostaglandin E2. 27 Because transfusion-related 
immunosuppression s thought o be nonspecific, one 
would expect increases in tumor recurrences and in- 
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fectious complications, as well as decreased survival 
duration, after transfusion. Indeed, various authors 
have documented increases in tumor recurrence and 
infections concomitant with perioperative transfusions 
in several cancers, including colon, hepat0cellular, 
lung, and sarcoma. 2'4'8'n'29-31 The patients in this 
study, however, showed no increases in either local o r  
distant umor ecurrences, and infectious complication 
rates were the same even though the total number of 
complications was markedly increased with blood 
transfusions ('Table IV). In addition, we saw no signif- 
icant depressJion of lymphocytes after transfusion, as 
has been described by others. 28 These findings suggest 
that a large immunosuppressive effect was not present 
and perhaps other factors accounted for the shorter 
survival duration after blood transfusion. 
In further analysis, we found that blood transfu- 
sions were associated with an increase in predomi- 
nantly noninfectious complications, which were as- 
sociated with a marked decrease in survival duration 
(Fig. 3), This observation raised the possibility that 
the decreased survival duration we observed with 
high-volume blood transfusion was a result not of 
the immunosuppressive effects of the transfused 
blood but rather of its close association with post- 
operative complications. Indeed, the addition of 
complications to our multivariate analysis elimi- 
nated blood transfusion as a significant predictor of 
decreased survival and at the same time had no 
effect on the other predictors. Because the compli- 
cations were for the most part noninfectious and 
therefore not attributable to immune suppression, 
the transfusion of blood appears to be only a marker 
for poor outcome rather than a causative factor. The 
clinical ramifications of this finding are important 
because in litany instances the transfusion of blood 
is essential for a good short-term outcome, and the 
withholding of blood could be detrimental to the 
immediate clinical situation. 
To our knowledge, this is the first published study 
to evaluate the effect of blood transfusions on 
survival duration in esophageal cancer and to doc- 
ument the close association of blood transfusions 
and postoperative complications in patients with this 
disease. Whether these findings are applicable to 
other cancers remains to be determined. The bio- 
logic features of esophageal tumors may be different 
from those of other types of cancer and therefore 
not sensitive to the immunosuppressive properties 
of blood. Alternatively, the decrease, in survival 
duration reported with other types of cancer after 
blood transfusion may also be related to an in- 
creased number of postoperative complications 
rather than any immunosuppressive effect of blood. 
It would be interesting if future studies evaluating 
the role of blood products on survival included 
postoperative complications in their analysis. 
In summary, our study showed that there was an 
association between perioperative blood transfu. 
sions and decreased survival duration in esophageal 
cancer. The association, however, may not have 
been causally related to blood immunosuppression 
but rather to the poor clinical situation that neces- 
sitated blood transfusions, which led to an increased 
number of postoperative complications and a subset 
of patients with a resultant poor outcome. The 
transfusion of blood products hould still be mini- 
mized when possible to avoid risks such as hepatitis, 
acquired immunodeficiency s ndrome, anaphylaxis, 
and transfusion reaction. The clinician need not 
forego transfusion i  esophageal cancer because of a 
fear that blood product immunosuppression will 
decrease cure after esophageal resection. 
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